Inventiva (CHIX:IVAP) Long-Term Debt: €26.82 Mil (As of Dec. 2025)


CHIX:IVAP Inventiva SA CHIX:IVAP
53 GF Score
Price €3.06
GF Value €0.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Long-Term Debt?

Inventiva CHIX:IVAP 53 Long-Term Debt is €26.82 Mil as of Dec. 2025. GuruFocus rates CHIX:IVAP with a GF Score™ of 53/100 and a GF Value™ of €0.24 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Inventiva's Long-Term Debt for the quarter that ended in Dec. 2025 was €26.82 Mil.

Inventiva's quarterly Long-Term Debt increased from Dec. 2024 (€46.33 Mil) to Jun. 2025 (€51.60 Mil) but then declined from Jun. 2025 (€51.60 Mil) to Dec. 2025 (€26.82 Mil).

Inventiva's annual Long-Term Debt increased from Dec. 2023 (€27.91 Mil) to Dec. 2024 (€46.33 Mil) but then declined from Dec. 2024 (€46.33 Mil) to Dec. 2025 (€26.82 Mil).

Inventiva  (CHIX:IVAp) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Inventiva Long-Term Debt Related Terms

Inventiva Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Inventiva's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inventiva Long-Term Debt Chart

Inventiva Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.75 25.43 27.91 46.33 26.82

Inventiva Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.91 43.54 46.33 51.60 26.82
CHIX:IVAP
53GF Score
Inventiva SA CHIX:IVAP
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €26.82 Mil mean?
Inventiva (CHIX:IVAP) has a Long-Term Debt of €26.82 Mil as of Dec. 2025.
Is Inventiva's Long-Term Debt too high?
Inventiva's current Long-Term Debt is €26.82 Mil. Overall, Inventiva has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inventiva's Long-Term Debt compare to VRTX and REGN?
Inventiva's Long-Term Debt of €26.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Inventiva's current Long-Term Debt is €26.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inventiva stock overvalued right now?
Based on GuruFocus' analysis, Inventiva (CHIX:IVAP) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €3.06 — trading 1175% above its estimated fair value. The current Long-Term Debt is €26.82 Mil. Inventiva's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Inventiva (CHIX:IVAP), the current Long-Term Debt is €26.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inventiva (CHIX:IVAP) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of €3.06 is trading 1175% above its estimated GF Value™ of €0.24. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for CHIX:IVAP:

  • Long-Term Debt: €26.82 Mil
  • GF Value™: €0.24 vs. price of €3.06 (1175% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the CHIX:IVAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
53GF Score

Get the complete analysis for CHIX:IVAP

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.06
Price
€0.24
GF Value